本页面由Tiger Trade Technology Pte. Ltd.提供服务

诺和诺德

36.53
-0.5500-1.48%
盘前35.71-0.8200-2.24%06:30 EDT
成交量:2,636.77万
成交额:9.65亿
市值:1,621.59亿
市盈率:10.09
高:37.00
开:36.49
低:36.18
收:37.08
52周最高:81.44
52周最低:35.85
股本:44.39亿
流通股本:31.88亿
量比:1.59
换手率:0.83%
股息:1.72
股息率:4.71%
每股收益(TTM):3.62
每股收益(LYR):3.62
净资产收益率:60.70%
总资产收益率:17.43%
市净率:5.68
市盈率(LYR):10.09

数据加载中...

2026/02/04

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/06/27

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/06/27

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/05/30

关联方拟减持公告

Form 144 | Innate Pharma SA 10% 股东 Novo Nordisk A/S 拟减持921897股,总价约197万美元
2025/02/05

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/21

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/06/21

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/01/31

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/11/24

SEC问询函

Form CORRESP - Correspondence
2023/11/09

SEC问询函

Form CORRESP - Correspondence
2023/10/20

SEC问询函

Form CORRESP - Correspondence
2023/09/29

SEC问询函

Form CORRESP - Correspondence
2023/09/13

SEC问询函

Form CORRESP - Correspondence
2023/06/28

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/06/28

员工持股计划

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/02/01

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/06/28

员工持股计划

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/06/28

员工持股计划

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/03/24

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/02

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]